Squibb Institute

Bristol Myers Squibb (BMS) is a global biopharmaceutical leader formed through the 1989 merger of Bristol-Myers and Squibb, incorporating the legacy of the Squibb Institute for Medical Research. The company is dedicated to discovering and developing innovative medicines for patients with serious diseases, particularly in oncology, hematology, immunology, and cardiovascular health. BMS is recognized for pioneering immuno-oncology with therapies like Opdivo and Yervoy, and for its market-leading anticoagulant Eliquis. Following the acquisition of Celgene, the company has significantly expanded its portfolio in hematology and cell therapy, including CAR-T products like Abecma and Breyanzi. With a robust R&D pipeline and a focus on diverse modalities such as targeted protein degradation and small molecules, BMS continues to be a major driver of pharmaceutical innovation. The company's historical roots in the Squibb Institute represent a long-standing commitment to scientific excellence and medical advancement.